.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB05_Rifapentine.Rifapentine_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB05_Rifapentine.Rifapentine_1| name: | Rifapentine_1 |
| ATC code: | J04AB05_1 | route: | oral |
| n-compartments | 2 |
Rifapentine is a long-acting rifamycin antibiotic used primarily in the treatment of tuberculosis (TB), including latent TB infection and active pulmonary TB. It acts by inhibiting DNA-dependent RNA polymerase in Mycobacterium tuberculosis. Rifapentine is approved by several regulatory agencies including the FDA and is commonly used in combination regimens with other anti-tuberculous agents.
Pharmacokinetic parameters in HIV-positive subjects with latent TB receiving weekly 900 mg oral dosing.
Marshall, JD, et al., & Kearns, GL (1999). Rifapentine pharmacokinetics in adolescents. The Pediatric infectious disease journal 18(10) 882–888. DOI:10.1097/00006454-199910000-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10530584
Langdon, G, et al., & Simonsson, US (2005). Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrobial agents and chemotherapy 49(11) 4429–4436. DOI:10.1128/AAC.49.11.4429-4436.2005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16251279
Zvada, SP, et al., & McIlleron, HM (2010). Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrobial agents and chemotherapy 54(8) 3390–3394. DOI:10.1128/AAC.00345-10 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20516273